The glycine site of NMDA receptors--a target for treatment of schizophrenia

Comment

Joachim F Hallmayer. Curr Psychiatry Rep. 2006 Jun.

. 2006 Jun;8(3):171-3.

doi: 10.1007/s11920-006-0019-x.

No abstract available

Comment on

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M. Heresco-Levy U, et al. Biol Psychiatry. 2005 Mar 15;57(6):577-85. doi: 10.1016/j.biopsych.2004.12.037. Biol Psychiatry. 2005. PMID: 15780844 Clinical Trial.
D-alanine added to antipsychotics for the treatment of schizophrenia.
Tsai GE, Yang P, Chang YC, Chong MY. Tsai GE, et al. Biol Psychiatry. 2006 Feb 1;59(3):230-4. doi: 10.1016/j.biopsych.2005.06.032. Epub 2005 Sep 9. Biol Psychiatry. 2006. PMID: 16154544 Clinical Trial.
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Lane HY, et al. Arch Gen Psychiatry. 2005 Nov;62(11):1196-204. doi: 10.1001/archpsyc.62.11.1196. Arch Gen Psychiatry. 2005. PMID: 16275807 Clinical Trial.